Another thing to note, with Carfilzomib patent protection expiring in 2027, it's possibly not only Amgen that could see value in these results.
Whilst Amgen may currently have the most to gain from a Carfilzomib/Bisantrene combination in terms of protecting their revenue stream, come 2027 another party could potentially pursue a combination of generic Carfilzomib and Bisantrene should a favourable deal with Amgen not eventuate.
This, as well as the timeframe, should at least help put some pressure on Amgen as it means Race isn't necessarily in a "take it or leave it" situation with them.
With RC220 on the verge of hitting the clinic, hopefully Race can begin to convert some of these pre-clinical synergies into something much more material in nature. There's too much work to do to here for Race to go it alone on everything.
- Forums
- ASX - By Stock
- Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model
Another thing to note, with Carfilzomib patent protection...
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.87 |
Change
-0.155(7.67%) |
Mkt cap ! $317.5M |
Open | High | Low | Value | Volume |
$2.03 | $2.08 | $1.86 | $706.9K | 357.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2637 | $1.87 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.87 | 577 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2637 | 1.865 |
1 | 10216 | 1.855 |
2 | 5250 | 1.850 |
1 | 971 | 1.845 |
1 | 971 | 1.835 |
Price($) | Vol. | No. |
---|---|---|
1.870 | 577 | 1 |
1.880 | 355 | 1 |
1.900 | 2000 | 1 |
1.930 | 971 | 1 |
1.935 | 284 | 1 |
Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Chairman
Nick Poll
Executive Chairman
Previous Video
Next Video
SPONSORED BY The Market Online